Neon Therapeutics’ Vaccine Study Demonstrates Prolonged Cancer Survival

NEO-PV-01, in combination with OPDIVO® (nivolumab), broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical durability for a personal neoantigen-based therapy in the metastatic cancer setting

Demonstrated prolonged and consistent improvements in progression-free survival (PFS) that compare favorably to historical monotherapy checkpoint inhibitor data in each of the three distinct tumor types in trial of NEO-PV-01

Median PFS not yet reached at 13.4-month median follow-up in metastatic melanoma; median PFS of 5.6 months in metastatic non-small cell lung cancer; and median PFS of 5.6 months in metastatic bladder cancer

Data from multicenter Phase 1b trial support future randomized Phase 2 development of NEO-PV-01

Conference call today at 8:30 A.M. ET: The live webcast can be accessed on the investor page of Neon’s website at https://ir.neontherapeutics.com/. The conference call can be accessed by dialing (866) 353-0265 and using the conference ID 5596197. A replay of the webcast will be available on Neon’s website approximately two hours after the completion of the event and will be archived for up to 30 days.

https://www.marketscreener.com/NEON-THERAPEUTICS-INC-44388574/news/Neon-Therapeutics-Personal-Neoantigen-Vaccine-Study-Demonstrates-Prolonged-Progression-Free-Surviva-28903881/